ERBB2 and breast carcinoma: This approach was applied to analyze samples containing a mixture of exosomes derived from four breast cancer cell lines (MCF-7, SKBR-3, MDA-MB-231 and BT474) in a 50% FBS medium, as well as four breast cancer subtypes (luminal A/B, HER2, triple negative) in human serum samples [177].